DRUG ACCOMMODATING DEVICE OF SOLID ORAL FORMULATION, AND ORAL ADMINISTRATION AND DELIVERY APPARATUS COMPRISING SAME

Abstract

A drug accommodating device of a solid oral formulation and an oral administration and delivery apparatus comprising same. The drug accommodating device comprises a filtering component and a supporting component; the filtering component and the supporting component cooperate with each other to form a space used for bearing drug particles or multiple pills; the filtering component has one or more pore channels allowing a liquid to pass; the pore channels are distributed in the filtering component in an up-down intricate intersection mode; alternatively, a water-soluble polymer material layer is provided on the filtering component. Alternatively, the drug accommodating device is a cylindrical structure with a top end being an opening and a bottom part being a screen mesh; the inner surface of the screen mesh is provided with the water-soluble polymer material layer; an inner cavity having the cylindrical structure above water-soluble polymer material layer is used for accommodating the drug particles or multiple pills. The drug accommodating device can overcome the problem that fluid resistance is large when the drug particles or multiple pills are leaked and sipped.

Claims

1. A drug accommodating apparatus of a solid oral preparation, which comprises a filtering component and a supporting component for supporting the filtering component, wherein the filtering component and the supporting components cooperate with each other to form space for bearing drug granules or multi-particulates, and the filtering component has one or more pore channels allowing a liquid to pass; and when the thickness of the filtering component is more than 0.5 mm, the pore channels are distributed in the filtering component in an up-down intricate intersection mode, so that the drug granules or multi-particulates cannot pass through.

2. The drug accommodating apparatus according to claim 1, wherein the filtering component is a filter membrane; the shape of the filter membrane is preferably a cylindrical structure; the thickness of the filter membrane is preferably 0.5-20 mm, more preferably 0.5-15 mm, and further more preferably 0.5-10 mm; preferably, upper and lower surfaces and the inner pore channels of the filter membrane are arranged in an irregular and intricately crossed structure, more preferably a spongy porous structure or a fluffy structure formed by irregularly stacking and pressing multiple layers of fibers; the pore diameter of the filter membrane is preferably 1-500 μm, more preferably 20-400 μm and further more preferably 40-300 μm; the effective diameter of the filter membrane is 4-20 mm, preferably 6-15 mm, and further more preferably 8 mm-12 mm; and/or, the particle sizes of the drug granules or multi-particulates are 1-5000 μm, preferably 25-2000 μm, and more preferably 50-1000 μm; preferably, when the particle sizes of the drug granules or multi-particulates are in the range of 50-1000 μm, the pore diameter of the filtering component is 40-300 μm; and/or, the active pharmaceutical ingredients contained in the drug granules or multi-particulates comprise but not limited to one or more of dabigatran etexilate or pharmaceutically acceptable salts thereof, apixaban, rivaroxaban, levodopa-carbidopa, montelukast, lansoprazole, omeprazole, esomeprazole, amoxicillin, clarithromycin, azithromycin, metronidazole, rifampicin, sulfasalazine, acetaminophen, dextromethorphan, doxylamine, pseudo ephedrine, diphenhydramine, amphetamine, methylphenidate, deferasirox, ivacaftor, lumacaftor, tacrolimus, diazepam, clobazam, vigabatrin, bosentan, melatonin, biotin, sodium dimercaptosuccinate, amlodipine and esmolol.

3. The drug accommodating apparatus according to claim 1, wherein the structure of the supporting component is as follows: the supporting component is arranged on upper and lower surfaces of the filtering component and clamps the filtering component in the middle, or the filtering component is wrapped inside in a cage structure; preferably, the structure of the supporting component is any one of the following structures: the supporting component comprises an upper supporting component and a lower supporting component, which can be closed with each other and hold the filtering component in the middle, and the space above the upper supporting component and the filtering component is used for accommodating drug granules or multi-particulates; or the supporting component comprises a filter-component accommodating component and a drug accommodating component, both of which have a pore-like structure end and an open end, wherein the pore-like structure end has one or more holes allowing a liquid to pass through, and the open end of the filter-component accommodating component and the pore-like structure end of the drug accommodating component can be closed to form a cavity for accommodating the filtering component; and the open end of the drug accommodating component is an open tubular structure for accommodating drug granules or multi-particulates; or the supporting component comprises a cage-like supporting component with an upward opening and an upper cover matched with the cage-like supporting component, wherein the upper cover is provided with a pore channel for drug granules or multi-particulates and a liquid to circulate, and the cage-like supporting component and the upper cover can enclose to form hollow space and limit the filtering component in the space, and the space above the upper cover and the filtering component is used for accommodating the drug granules or multi-particulates.

4. An oral delivery device (i) or (ii), which comprises the drug accommodating apparatus according to claim 1, the oral delivery device (i) further comprises a tubular component with two end openings and an inner cavity, wherein one end opening is a first opening and the other end opening is a second opening, and the inner cavity is communicated with the first opening and the second opening; and the drug accommodating apparatus is externally connected to a free end of the first opening, and makes space for bearing drug granules or multi-particulates communicated with the inner cavity; the oral delivery device (ii) further comprises a tubular component with two end openings and an inner cavity, wherein one end opening is a first opening and the other end opening is a second opening, and the inner cavity is communicated with the first opening and the second opening; the drug accommodating apparatus is arranged in the inner cavity and close to the first opening, and space for bearing drug granules or multi-particulates is communicated with the second opening; and the diameter of the first opening is smaller than the minimum diameter of the drug accommodating apparatus.

5. The oral delivery device according to claim 4, wherein the drug accommodating apparatus of the oral delivery device (i) is placed outside the tubular component, and is maintained at the first opening of the tubular component by a fixed sleeve or threaded connection; and/or, the diameter of the second opening is smaller than the minimum diameter of the drug accommodating apparatus of the oral delivery device (ii); and/or, the second opening is also provided with a top cover for sealing; and/or, the tubular component is a straight straw; the straight straw is preferably provided with at least one fold structure; preferably, the fold structure has a pair of wings and a turning end; and the fold structure can be stretched or contracted along the axial direction of the tubular component, and a turbulent flow is formed during stretching; and/or, the tubular component has at least two tube sections which are hermetically connected and can be axially stretched or contracted along the tubular component; and when the tubular component is in a stretched state, a turbulent flow generating part with at least one step structure is formed, wherein, when the number of the tube sections is 3, the inner diameters of the first tube section and the third tube section in the direction from the first opening to the second opening are the same, the outer diameter of the second tube section is smaller than the inner diameter of the first tube section, and each tube section can be axially stretched or contracted along other tube sections; or, the inner diameter of the first tube section, the outer diameter and the inner diameter of the second tube section, the outer diameter of the third tube section in the direction from the first opening to the second opening are gradually reduced, and each tube section can be axially stretched or contracted along other tube sections; wherein, when the number of the tube sections is 4, the inner diameters of the first tube section and the third tube section in the direction from the first opening to the second opening are the same, and the inner diameters of the second tube section and the fourth tube section are the same, wherein the inner diameter of the second tube section is smaller than that of the first tube section, and each tube section can be axially stretched or contracted along other tube sections; or, the inner diameter thereof gradually decreases from the first tube section to the fourth tube section in the direction from the first opening to the second opening, and each tube section can be axially stretched or contracted along other tube sections.

6. (canceled)

7. (canceled)

8. A drug accommodating apparatus of a solid oral preparation, characterized by having a structure 1 or a structure 2: structure 1: the drug accommodating apparatus comprises a filtering component and a supporting component for supporting the filtering component, wherein the filtering component and the supporting components cooperate with each other to form space for bearing drug granules or multi-particulates, and the filtering component has one or more pore channels allowing a liquid to pass; and the filtering component is also provided with a water-soluble polymer material layer, so that the drug granules or multi-particulates cannot pass through; and structure 2: the drug accommodating apparatus is a cylindrical structure with a top end being an opening and a bottom part being a screen mesh, and the inner surface of the screen mesh is provided with a water-soluble polymer material layer, and the inner cavity having the cylindrical structure above the water-soluble polymer material layer is used for accommodating drug granules or multi-particulates.

9. The drug accommodating apparatus according to claim 8, wherein the filtering component is a filter membrane; the shape of the filter membrane is preferably a wafer structure; the thickness of the filter membrane is preferably 0.01-0.5 mm, more preferably 0.1-0.3 mm; preferably, the pore channel in the filter membrane connects and penetrates the upper and lower surfaces of the filter membrane in a straight line way; the pore diameter of the filter membrane is preferably 1-500 μm, more preferably 20-400 μm, and further more preferably 40-300 μm; the effective diameter of the filter membrane is preferably 4-20 mm, more preferably 6-15 mm, and further more preferably 8 mm-12 mm; and/or, the particle sizes of the drug granules or multi-particulates are 1-5000 μm, preferably 25-2000 μm, and more preferably 50-1000 μm; preferably, when the particle sizes of the drug granules or multi-particulates are in the range of 50-1000 μm, the pore diameter of the filtering component in the structure 1 or the screen mesh in the structure 2 is 40-300 μm; and/or, the active pharmaceutical ingredients contained in the drug granules or multi-particulates comprise but not limited to one or more of dabigatran etexilate or pharmaceutically acceptable salts thereof, apixaban, rivaroxaban, levodopa-carbidopa, montelukast, lansoprazole, omeprazole, esomeprazole, amoxicillin, clarithromycin, azithromycin, metronidazole, rifampicin, sulfasalazine, acetaminophen, dextromethorphan, doxylamine, pseudo ephedrine, diphenhydramine, amphetamine, methylphenidate, deferasirox, ivacaftor, lumacaftor, tacrolimus, diazepam, clobazam, vigabatrin, bosentan, melatonin, biotin, sodium dimercaptosuccinate, amlodipine and esmolol.

10. The drug accommodating apparatus according to claim 8, wherein the water-soluble polymer material layer has the following two structures: a continuous water-soluble polymer material layer is formed on the upper or lower surface of the filter membrane, or the polymer material completely blocks the pore channels of the filter membrane and forms a complete and compact water-soluble polymer material layer; and/or, the dissolution time of the water-soluble polymer material layer is less than or equal to 10 s; and/or, the molecular weight of the polymer material in the water-soluble polymer material layer is 2000-200000, preferably 2000-100000; and/or, the type of the polymer material in the water-soluble polymer material layer is selected from one or more of hydroxypropyl methylcellulose, copolyvidone, hydroxypropyl cellulose, hydroxyethyl cellulose (HEC), povidone, polyethylene glycol (PEG), gelatin, poloxamer, xanthan gum and Eudragit; and/or, in the forming process of the water-soluble polymer material layer, the weight gain of the polymer material is 0.01-60 mg/cm.sup.2, preferably 0.5-30 mg/cm.sup.2.

11. The drug accommodating apparatus according to claim 8, wherein the structure of the supporting component is any one of the following structures: the supporting component comprises an upper supporting component and a lower supporting component, which can be closed with each other and hold the filtering component in the middle, and the space above the upper supporting component and the filtering component is used for accommodating drug granules or multi-particulates; or the supporting component comprises a filter-component accommodating component and a drug accommodating component, both of which have a pore-like structure end and an open end, wherein the pore-like structure end has one or more holes allowing a liquid to pass through, and the open end of the filter-component accommodating component and the pore-like structure end of the drug accommodating component can be closed to form a cavity for accommodating the filtering component; and the open end of the drug accommodating component is an open tubular structure for accommodating drug granules or multi-particulates.

12. An oral delivery device (iii) or (iv), which comprises the drug accommodating apparatus according to claim 8, the oral delivery device (iii) further comprises a tubular component with two end openings and an inner cavity, wherein one end opening is a first opening and the other end opening is a second opening, and the inner cavity is communicated with the first opening and the second opening; and the drug accommodating apparatus is externally connected to a free end of the first opening, and makes space for bearing drug granules or multi-particulates communicated with the inner cavity; the oral delivery device (iv) further comprises a tubular component with two end openings and an inner cavity, wherein one end opening is a first opening and the other end opening is a second opening, and the inner cavity is communicated with the first opening and the second opening; the drug accommodating apparatus is arranged in the inner cavity and close to the first opening, and space for bearing drug granules or multi-particulates is communicated with the second opening; and the diameter of the first opening is smaller than the minimum diameter of the drug accommodating apparatus.

13. The oral delivery device according to claim 12, wherein the drug accommodating apparatus of the oral delivery device (iii) is placed outside the tubular component, and is maintained at the first opening of the tubular component by a fixed sleeve or threaded connection; and/or, the diameter of the second opening is smaller than the minimum diameter of the drug accommodating apparatus of the oral delivery device (iv); and/or, the second opening is also provided with a top cover for sealing; and/or, the tubular component is a straight straw; the straight straw is preferably provided with at least one fold structure; preferably, the fold structure has a pair of wings and a turning end; and the fold structure can be stretched or contracted along the axial direction of the tubular component, and a turbulent flow is formed during stretching; and/or, the tubular component has at least two tube sections which are hermetically connected and can be axially stretched or contracted along the tubular component; and when the tubular component is in a stretched state, a turbulent flow generating part with at least one step structure is formed, wherein, when the number of the tube sections is 3, the inner diameters of the first tube section and the third tube section in the direction from the first opening to the second opening are the same, the outer diameter of the second tube section is smaller than the inner diameter of the first tube section, and each tube section can be axially stretched or contracted along other tube sections; or, the inner diameter of the first tube section, the outer diameter and the inner diameter of the second tube section, the outer diameter of the third tube section in the direction from the first opening to the second opening are gradually reduced, and each tube section can be axially stretched or contracted along other tube sections; wherein, when the number of the tube sections is 4, the inner diameters of the first tube section and the third tube section in the direction from the first opening to the second opening are the same, and the inner diameters of the second tube section and the fourth tube section are the same, wherein the inner diameter of the second tube section is smaller than that of the first tube section, and each tube section can be axially stretched or contracted along other tube sections; or, the inner diameter thereof gradually decreases from the first tube section to the fourth tube section in the direction from the first opening to the second opening, and each tube section can be axially stretched or contracted along other tube sections.

14. (canceled)

15. (canceled)

16. A drug accommodating apparatus of a solid oral preparation, which comprises a filtering component and a supporting component for supporting the filtering component, wherein the filtering component and the supporting components cooperate with each other to form space for bearing drug granules or multi-particulates, and the filtering component has one or more pore channels allowing a liquid to pass; and the pore channels are distributed in the filtering component in an up-down intricate intersection mode, and a water-soluble polymer material layer is also arranged on the filtering component, so that the drug granules or multi-particulates cannot pass through.

17. The drug accommodating apparatus according to claim 16, wherein the filtering component is a filter membrane; the shape of the filter membrane is preferably a cylindrical structure; the thickness of the filter membrane is preferably 0.3-20 mm, more preferably 0.5-15 mm, and further more preferably 0.5-10 mm; preferably, upper and lower surfaces and the inner pore channels of the filter membrane are arranged in an irregular and intricately crossed structure, more preferably a spongy porous structure or a fluffy structure formed by irregularly stacking and pressing multiple layers of fibers; the pore diameter of the filter membrane is preferably 1-500 μm, more preferably 20-400 μm and further more preferably 40-300 μm; the effective diameter of the filter membrane is 4-20 mm, preferably 6-15 mm, and further more preferably 8 mm-12 mm; and/or particle sizes of the drug granules or multi-particulates are 1-5000 μm, preferably 25-2000 μm, and more preferably 50-1000 μm; preferably, when the particle sizes of the drug granules or multi-particulates are in the range of 50-1000 μm, the pore diameter of the filtering component is 40-300 μm; and/or the active pharmaceutical ingredients contained in the drug granules or multi-particulates comprise but not limited to one or more of dabigatran etexilate or pharmaceutically acceptable salts thereof, apixaban, rivaroxaban, levodopa-carbidopa, montelukast, lansoprazole, omeprazole, esomeprazole, amoxicillin, clarithromycin, azithromycin, metronidazole, rifampicin, sulfasalazine, acetaminophen, dextromethorphan, doxylamine, pseudo ephedrine, diphenhydramine, amphetamine, methylphenidate, deferasirox, ivacaftor, lumacaftor, tacrolimus, diazepam, clobazam, vigabatrin, bosentan, melatonin, biotin, sodium dimercaptosuccinate, amlodipine and esmolol.

18. The drug accommodating apparatus according to claim 16, wherein the water-soluble polymer material layer has the following two structures: a continuous water-soluble polymer material layer is formed on the upper or lower surface of the filter membrane, or the polymer material completely blocks the pore channels of the filter membrane and forms a complete and compact water-soluble polymer material layer; and/or, the dissolution time of the water-soluble polymer material layer is less than or equal to 10 s; and/or, the molecular weight of the polymer material in the water-soluble polymer material layer is 2000-200000, preferably 2000-100000; and/or, the type of the polymer material in the water-soluble polymer material layer is selected from one or more of hydroxypropyl methylcellulose, copolyvidone, hydroxypropyl cellulose, hydroxyethyl cellulose (HEC), povidone, polyethylene glycol (PEG), gelatin, poloxamer, xanthan gum and Eudragit; and/or, in the forming process of the water-soluble polymer material layer, the weight gain of the polymer material is 0.01-60 mg/cm.sup.2, preferably 0.5-30 mg/cm.sup.2.

19. The drug accommodating apparatus according to claim 16, wherein the structure of the supporting component is any one of the following structures: the supporting component comprises an upper supporting component and a lower supporting component, which can be closed with each other and hold the filtering component in the middle, and the space above the upper supporting component and the filtering component is used for accommodating drug granules or multi-particulates; or the supporting component comprises a filter-component accommodating component and a drug accommodating component, both of which have a pore-like structure end and an open end, wherein the pore-like structure end has one or more holes allowing a liquid to pass through, and the open end of the filter-component accommodating component and the pore-like structure end of the drug accommodating component can be closed to form a cavity for accommodating the filtering component; and the open end of the drug accommodating component is an open tubular structure for accommodating drug granules or multi-particulates.

20. An oral delivery device (v) or (vi) which comprises the drug accommodating apparatus according to claim 16, the oral delivery device (v) further comprises a tubular component with two end openings and an inner cavity, wherein one end opening is a first opening and the other end opening is a second opening, and the inner cavity is communicated with the first opening and the second opening; and the drug accommodating apparatus is externally connected to a free end of the first opening, and makes space for bearing drug granules or multi-particulates communicated with the inner cavity; the oral delivery device (vi) further comprises a tubular component with two end openings and an inner cavity, wherein one end opening is a first opening and the other end opening is a second opening, and the inner cavity is communicated with the first opening and the second opening; the drug accommodating apparatus is arranged in the inner cavity and close to the first opening, and space for bearing drug granules or multi-particulates is communicated with the second opening; and the diameter of the first opening is smaller than the minimum diameter of the drug accommodating apparatus.

21. The oral delivery device according to claim 20, wherein the drug accommodating apparatus of the oral delivery device (v) is placed outside the tubular component, and is maintained at the first opening of the tubular component by a fixed sleeve or threaded connection; and/or, the diameter of the second opening is smaller than the minimum diameter of the drug accommodating apparatus of the oral delivery device (vi); and/or, the second opening is also provided with a top cover for sealing; and/or, the tubular component is a straight straw; the straight straw is preferably provided with at least one fold structure; preferably, the fold structure has a pair of wings and a turning end; and the fold structure can be stretched or contracted along the axial direction of the tubular component, and a turbulent flow is formed during stretching; and/or, the tubular component has at least two tube sections which are hermetically connected and can be axially stretched or contracted along the tubular component; and when the tubular component is in a stretched state, a turbulent flow generating part with at least one step structure is formed, wherein, when the number of the tube sections is 3, the inner diameters of the first tube section and the third tube section in the direction from the first opening to the second opening are the same, the outer diameter of the second tube section is smaller than the inner diameter of the first tube section, and each tube section can be axially stretched or contracted along other tube sections; or, the inner diameter of the first tube section, the outer diameter and the inner diameter of the second tube section, the outer diameter of the third tube section in the direction from the first opening to the second opening are gradually reduced, and each tube section can be axially stretched or contracted along other tube sections; wherein, when the number of the tube sections is 4, the inner diameters of the first tube section and the third tube section in the direction from the first opening to the second opening are the same, and the inner diameters of the second tube section and the fourth tube section are the same, wherein the inner diameter of the second tube section is smaller than that of the first tube section, and each tube section can be axially stretched or contracted along other tube sections; or, the inner diameter thereof gradually decreases from the first tube section to the fourth tube section in the direction from the first opening to the second opening, and each tube section can be axially stretched or contracted along other tube sections.

22. (canceled)

23. (canceled)

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0151] FIG. 1 is a schematic structural diagram of supporting components and a filtering component of a drug accommodating apparatus of Embodiment 1, wherein 1a displays a lower supporting component, 1b displays a filtering component, and 1c displays an upper supporting component;

[0152] FIG. 2 is a schematic assembly diagram of supporting components and a filtering component of a drug accommodating apparatus of Embodiment 1, wherein 2a displays situations before assembly and 2b displays situations after assembly;

[0153] FIG. 3 is a schematic structural diagram of a built-in oral delivery device formed by assembling a drug accommodating apparatus and a straw of Embodiment 1;

[0154] FIG. 4 is a schematic structural diagram of supporting components and a filtering component of a drug accommodating apparatus according to Embodiment 2, wherein 4a displays a cage-like supporting component, 4b displays a filtering component, and 4c displays an upper cover of the cage-like supporting component;

[0155] FIG. 5 is a schematic assembly diagram of supporting components and a filtering component of a drug accommodating apparatus of Embodiment 2;

[0156] FIG. 6 is a schematic diagram of a built-in oral delivery device formed by assembling a drug accommodating apparatus and a straw of Embodiment 2;

[0157] FIG. 7 is a schematic diagram of a built-in oral delivery device of Embodiments 1-3 under use of a straw, wherein 7a displays situations before sipping and 7b displays situations after sipping;

[0158] FIG. 8 is a schematic structural diagram of a filter-component accommodating component, a filtering component and a drug accommodating component of a drug accommodating apparatus of Embodiment 4, wherein 8a displays a filter-component accommodating component, 8b displays a filtering component and 8c displays a drug accommodating component;

[0159] FIG. 9 is a schematic diagram of assembly of a filter-component accommodating component, a filtering component and a drug accommodating component of a drug accommodating apparatus of Embodiment 4, wherein 9a displays situations before assembly and 9b displays situations after assembly;

[0160] FIG. 10 is a schematic diagram of a built-out oral delivery device formed by assembling a drug accommodating apparatus and a straw of Embodiment 4;

[0161] FIG. 11 is a schematic diagram of a built-out oral delivery device of Embodiment 4 under use of a straw, wherein 11a displays situations before sipping and 11b displays situations after sipping;

[0162] FIG. 12 is a section view of an irregular and intricately crossed structure of an internal pore channel of a filtering component of an embodiment;

[0163] FIG. 13 is a schematic structural diagram of a drug accommodating apparatus of Embodiment 8; and

[0164] FIG. 14 is a schematic structural diagram of an oral delivery device of Embodiment 8.

DETAILED DESCRIPTION OF THE PREFERABLE EMBODIMENT

Embodiment 1 (Water-Soluble Polymer Material Layer+Built-In)

[0165] As shown in FIGS. 1-3, a filter membrane with a pore diameter of 150 μm and a thickness of 0.2 mm and made of polypropylene is cut into a wafer with a diameter of 1 cm. The filter membrane is soaked in a 10% hydroxypropyl methylcellulose E3 solution, and then dried in an oven. After drying (weight gain is 6.4 mg/cm.sup.2), the filter membrane is placed between two polyethylene wafers with a diameter of 1 cm and a thickness of 3 mm, and the two polyethylene wafers are covered with grids with a diameter of 2 mm×2 mm which is vertically through. The surface of one polyethylene wafer is provided with four protrusions with a diameter of 2 mm, and the symmetrical position of the surface of the other polyethylene wafer is provided with four pits with a diameter of 2 mm. The two wafers are mechanically condensed by a concave-convex structure, and the filter membrane is tightly fixed in the middle to form a drug accommodating apparatus. The device is placed in a fold straw with an inner diameter of 1.05 cm from a nozzle at one end contacting with a liquid, and the drug accommodating apparatus can stay in the straw by bending the nozzle inward.

Embodiment 2 (Intricately Crossed Pore Channel Structure+Built-In)

[0166] As shown in FIGS. 4-6, a filter membrane made of polypropylene with a pore diameter of 300 μm and a thickness of 6 mm (the filter membrane is provided with intricately crossed irregular pore channels) (FIG. 12 is a schematic diagram of the internal pore channel structure of the filtering component in FIG. 4 and FIG. 8) is cut into a cylinder with a diameter of 8 mm. The cylindrical filter membrane is placed in a cylindrical filter membrane accommodating device with an inner cavity diameter of 8.1 mm and a height of 6 mm; the bottom and a cover of the cylinder are covered with 2 mm×2 mm grids which are vertically through; and the cylinder cover is fixed with a cylinder body by mechanical condensation, and the filter membrane is wrapped in the cylinder cover to form a drug accommodating apparatus. The device is placed in a fold straw with an inner diameter of 1.2 cm from a nozzle at the end contacting with the liquid, and the nozzle is bent inward, so that the drug accommodating apparatus can stay in the straw.

Embodiment 3 (Intricately Crossed Pore Channel Structure+Water Soluble Polymer Material Layer+Built-In)

[0167] As shown in FIGS. 1-3, a filter membrane with a pore diameter of 300 μm and a thickness of 1.5 mm and made of polypropylene (the filter membrane is provided with intricately crossed irregular pore channels) is cut into a wafer with a diameter of 1 cm. The filter membrane is soaked in a 10% hydroxypropyl methylcellulose E3 solution, and then dried in an oven. After drying (weight gain is 25.5 mg/cm.sup.2), the filter membrane is placed between two polyethylene wafers with a diameter of 1 cm and a thickness of 3 mm, and the two polyethylene wafers are covered with grids with a diameter of 2 mm×2 mm which is vertically through. The surface of one polyethylene wafer is provided with four protrusions with a diameter of 2 mm, and the symmetrical position of the surface of the other polyethylene wafer is provided with four pits with a diameter of 2 mm. The two wafers are mechanically condensed by a concave-convex structure, and the filter membrane is tightly fixed in the middle to form a drug accommodating apparatus. The device is placed in a fold straw with an inner diameter of 1.05 cm from a nozzle at one end contacting with a liquid, and the drug accommodating apparatus can stay in the straw by bending the nozzle inward.

[0168] The schematic structural diagrams of the devices of Embodiments 1, 2 and 3 in use are shown in FIG. 7.

Embodiment 4 (Intricately Crossed Pore Channel Structure+Built-Out)

[0169] As shown in FIGS. 8-11, a filter membrane with a pore diameter of 100 μm and a thickness of 2 mm and made of polypropylene (the filter membrane is provided with intricately crossed irregular pore channels) is cut into a wafer with a diameter of 12 mm. By an injection molding process, an accommodating component of a filtering component and a drug accommodating component are prepared. The filter-component accommodating component is a cylindrical structure with an inner diameter of 12.1 mm and an inner height of 4 mm, and the bottom of the cylinder is provided with a round hole with a diameter of 8 mm, which is vertically through; and the drug accommodating component has a cylindrical structure with an inner diameter of 9.1 mm and an inner height of 1.5 cm. The filter membrane is placed in the cylindrical structure of the filter-component accommodating component, and then the lower end of the drug accommodating component is pressed thereon, and both are condensed by a mechanical structure to fix the filter membrane in the middle, thus obtaining a drug accommodating apparatus. Then, the upper end of the drug accommodating apparatus is connected with a nozzle at an end, contacting a liquid, of a fold straw (inner diameter 8.6 mm). 504.1 mg of hot-melt granulated dabigatran etexilate mesylate particles (containing 75 mg dabigatran etexilate, particle size distribution as shown in Table 1) are filled into the drug accommodating apparatus through the upper end of the straw, and no particles leak through the drug accommodating apparatus. In use, one end of the straw with the drug accommodating apparatus is placed in the liquid, a patient sucks the liquid into the straw by sipping, and the liquid easily passes through the drug accommodating apparatus and pushes the dabigatran etexilate mesylate particles into the patient's mouth, thus completing drug administration.

TABLE-US-00001 TABLE 1 Particle size distribution of hot-melt granulated dabigatran etexilate mesylate particles Particle size range Percentage >355 μm 23.8% 250-355 μm 7.6% 180-250 μm 35.9% 180 μm 32.7%

Embodiment 5 (Intricately Crossed Pore Channel Structure+Water-Soluble Polymer Material Layer+Built-Out)

[0170] As shown in FIGS. 8-11, a filter membrane with a pore diameter of 300 μm and a thickness of 1.5 mm and made of polypropylene is provided with intricately crossed irregular channels, and is cut into a wafer with a diameter of 12 mm. The filter membrane is soaked in 10% Killidon VA64 ethanol solution, and then dried in an oven, and the weight gain after drying is 16.0 mg/cm.sup.2. By an injection molding process, an accommodating component of a filtering component and a drug accommodating component are prepared. The filter-component accommodating component is a cylindrical structure with an inner diameter of 12.1 mm and an inner height of 4 mm, and the bottom of the cylinder is provided with a round hole with a diameter of 8 mm, which is vertically through; and the drug accommodating component has a cylindrical structure with an inner diameter of 9.1 mm and an inner height of 1.5 cm. The filter membrane is placed in the cylindrical structure of the filter-component accommodating component, and then the lower end of the drug accommodating component is pressed thereon, and both are condensed by a mechanical structure to fix the filter membrane in the middle, thus obtaining a drug accommodating apparatus. Then, the upper end of the drug accommodating apparatus is connected with a nozzle at an end, contacting a liquid, of a fold straw (inner diameter 8.6 mm). 500 mg of D-mannitol pellets with a particle size ranging from 75 μm to 150 μm are filled into the cylinder of the drug accommodating apparatus through the upper end of the straw, and no multiple pills leak through the drug accommodating apparatus.

Embodiment 6 (Water-Soluble Polymer Material Layer+Built-Out)

[0171] As shown in FIGS. 8-11, a filter membrane with a pore diameter of 250 μm and a thickness of 0.3 mm and made of polypropylene is cut into a wafer with a diameter of 12 mm. The filter membrane is soaked in 10% Killidon VA64 ethanol solution, and then dried in an oven, and the weight gain after drying is 8.9 mg/cm.sup.2. By an injection molding process, an accommodating component of a filtering component and a drug accommodating component are prepared. The filter-component accommodating component is a cylindrical structure with an inner diameter of 12.1 mm and an inner height of 3 mm, and the bottom of the cylinder is provided with a round hole with a diameter of 8 mm, which is vertically through; and the drug accommodating component has a cylindrical structure with an inner diameter of 9.1 mm and an inner height of 1.5 cm. The filter membrane is placed in the cylindrical structure of the filter-component accommodating component, and then the lower end of the drug accommodating component is pressed thereon, and both are condensed by a mechanical structure to fix the filter membrane in the middle, thus obtaining a drug accommodating apparatus. Then, the upper end of the drug accommodating apparatus is connected with a nozzle at an end, contacting a liquid, of a fold suction tube (inner diameter 8.6 mm).

Embodiment 7 (Intricately Crossed Pore Channel Structure+Built-Out)

[0172] The drug accommodating apparatus in Embodiment 4 is assembled with a straw with a total length of 20 cm, an inner diameter of 8.6 mm and a fold length of 4 cm. The lower end of the drug accommodating apparatus is blocked with fingers, and the straw is filled with a liquid from the upper end. Under the action of gravity, the liquid in the device is emptied for about 2-3 s.

Embodiment 8 (Water-Soluble Polymer Material Layer+Built-Out)

[0173] As shown in FIGS. 13-14, a drug accommodating apparatus is prepared by an injection molding process. The drug accommodating apparatus has a cylindrical structure with an inner diameter of 9 mm, a height of 2 cm and a wall thickness of 1 mm; the inner diameter of the cylinder bottom is 9 mm, with a plurality of screen meshs with a pore diameter of 200 μm, which are vertically through; and the inner wall of a cylinder mouth is designed with two rings of raised annular structures, which are used to connect a straw in an external way. A 7.5% HPMC E3 aqueous solution is coated on the inner surface of the cylinder bottom and dried, and the weight gain is 17.7 mg/cm.sup.2, so that the drug accommodating apparatus is obtained.

Embodiment 9 (Intricately Crossed Pore Channel Structure+Built-Out)

[0174] As shown in FIGS. 8-11, a filter membrane with a pore diameter of 100 μm and a thickness of 2 mm and made of polypropylene (the filter membrane is provided with intricately crossed irregular pore channels) is cut into a wafer with a diameter of 16 mm. By an injection molding process, an accommodating component of a filtering component and a drug accommodating component are prepared. The filter-component accommodating component is a cylindrical structure with an inner diameter of 16.1 mm and an inner height of 4 mm, and the bottom of the cylinder is provided with a round hole with a diameter of 12 mm, which is vertically through; and the drug accommodating component has a cylindrical structure with an inner diameter of 12.5 mm and an inner height of 1.5 cm. The filter membrane is placed in the cylindrical structure of the filter-component accommodating component, and then the lower end of the drug accommodating component is pressed thereon, and both are condensed by a mechanical structure to fix the filter membrane in the middle, thus obtaining a drug accommodating apparatus. Then, the upper end of the drug accommodating apparatus is connected with a nozzle at an end, contacting a liquid, of a fold suction tube (inner diameter 12 mm). 320 mg of omeprazole enteric-coated multi-particulates (including 20 mg of omeprazole), 1334 mg of amoxicillin granules (including 1000 mg of amoxicillin) and 840 mg of clarithromycin granules (including 500 mg of clarithromycin) are filled into the drug accommodating device through the upper end of the straw, and no multi-particulates or granules leak through the drug accommodating apparatus. In use, one end of the straw with the drug accommodating apparatus is placed in a liquid, and a patient sucks the liquid into the straw by sipping, and the liquid easily passes through the drug accommodating apparatus and pushes the pills particles into the patient's mouth, thus completing drug administration. The particle size range of omeprazole enteric-coated multiple pills is 0.25-0.355 mm. See Table 2 and Table 3 for the particle size distribution of amoxicillin particles and clarithromycin particles.

TABLE-US-00002 TABLE 2 Particle size distribution of amoxicillin particles Particle size range Percentage 425-600 μm 22.8% 250-425 μm 33.6% 150-250 μm 25.7% <150 μm 17.9%

TABLE-US-00003 TABLE 3 Particle size distribution of clarithromycin. Particle size range Percentage 425-600 μm 32.1% 250-425 μm 16.7% 150-250 μm 28.9% <150 μm 2.3%

Embodiment 10 (Intricately Crossed Pore Channel Structure+Built-In)

[0175] The structure and other parameters of the present embodiment are the same as those of Embodiment 2, and leakage prevention effects realized are the same. The only difference is that the filter membrane in Embodiment 2 is replaced by a sponge-like porous structure, so that the present embodiment has an irregular and intricately crossed structure.

Embodiment 11 (Intricately Crossed Pore Channel Structure+Built-Out)

[0176] The structure and other parameters of the present embodiment are the same as those of Embodiment 4, and leakage prevention effects realized are the same. The only difference is that the filter membrane in Embodiment 4 is replaced by a fluffy structure formed by irregular stacking and pressing multiple layers of fibers, so that the present embodiment has an irregular and intricately crossed structure.

[0177] Although specific implementations of the present invention have been described above, it should be understood by those skilled in the art that these are only examples, and various changes or modifications can be made to the embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the attached claims.